Four Biotech Small Caps with Near Term Catalysts to Keep on Your Radar
January 27 2016 - 8:00AM
InvestorsHub NewsWire
Peregrine Pharmaceuticals, Inc. (NASDAQ:
PPHM) is a biopharmaceutical company focused on developing
therapeutics to stimulate the body's immune system to fight
cancer. Bavituximab, the company's lead immunotherapy
candidate, is in late-stage clinical development for the treatment
of both lung cancer and breast cancer.
Find out how Bavituximab works and get updates on its clinical
trials in the brief report you can read at this link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
Amarin Corp. Plc (NASDAQ:
AMRN) is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development is focused in
lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Amarin's first product, Vascepa®
(icosapent ethyl) capsules, is a highly pure EPA omega-3
prescription product.
In the brief report you can read at the link, find out about the
AMRN lead drug Vascepa and get the company’s 2015 financial figures
and guidance for 2016: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
Anavex Life Sciences Corp. (NASDAQ:
AVXL) is a biopharmaceutical company developing differentiated
therapeutics for the treatment of neurodegenerative diseases
including Alzheimer’s disease, other central nervous system
diseases, pain and various types of cancer. Anavex’s lead drug
candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX
2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical
trial for Alzheimer’s disease.
Get the information about ANAVEX-2-73, its potential applications
and updates on the company’s current Phase II clinical trials in
the brief report we’ve posted at this link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
Sunshine Biopharma Inc. (OTCQB:
SBFM) is a pharmaceutical company focused on drugs for the
treatment of various forms of cancer. The company is currently in
discussions with investment groups to securing funding for its drug
candidate Adva-27a development through Phase I clinical trials.
Adva-27a has proven to be effective at killing Multidrug Resistant
Cancer cells including Pancreatic Cancer cells, Small-Cell Lung
Cancer cells, Breast Cancer cells and Uterine Sarcoma cells.
Read about Adva-27a and its potential, along with the SBFM plans to
develop the drug candidate in the brief report you can find at this
link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
About Broad Street Alerts
We make the connection between sophisticated investors and high
quality micro and small cap companies. An issuer of reports that
provide a straightforward assessment of the profiled company. They
include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to anticipated revenues,
expenses, earnings, operating cash flows, the outlook for markets
and the demand for products. Forward-looking statements are no
guarantees of future performance and are inherently subject to
uncertainties and other factors which could cause actual results to
differ materially from the forward-looking statements. Such
statements are based upon, among other things, assumptions made by,
and information currently available to, management, including
management's own knowledge and assessment of the Company's industry
and competition. The Company refers interested persons to its most
recent Annual Report on Form 10-K and its other SEC filings for a
description of additional uncertainties and factors, which may
affect forward-looking statements. The company assumes no duty to
update its forward-looking statements
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party analyst. However, we are only human and may make
mistakes. If you notice any errors or omissions, please notify us.
This report was prepared for informational purposes only. A full
disclaimer can be found by viewing the full analyst report. We do
not hold any positions and have not been compensated in any form
for this press release and coinciding reports. For more information
and services provided beyond this press release please use contact
information provided below.
Contact: Editor@Broadstreetalerts.com
Source: Broad street alerts
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024